Skip to content
Axe Capital logo Axe Capital Trading News

Axe Capital Investments

Clear market notes built around the JSE, the rand, and what matters locally.

Axe Capital Trading News shares simple market takes on the stories moving South African shares, the rand, and a handful of major currency pairs.

What you will find here:

1. JSE shares, South African companies, and the local knock-on effects of big market news.

2. The rand, interest rates, and a small group of forex pairs, with USD/ZAR at the centre.

3. Global stories only when they can actually change how a local investor might act.

Latest market stories

IonQ Just Announced a Major Breakthrough. Should Investors Buy the Stock Now?
2026-09-27 10:15 • The Motley Fool Positive Axe Cap view: Selective

IonQ announced a breakthrough in quantum error correction with its first end-to-end, real-time quantum error-correction decoder running on a standard CPU. The stock rose 11% following the announcement and a partnership with Nvidia's Accelerated Quantum Research Center. However, the company remains unprofitable with a rich valuation, and the decoder was only validated on simulated data. The stock has fallen 40% over the past year, making it a high-risk, speculative investment suitable only for long-term investors.

Axe note: IonQ’s latest quantum error correction breakthrough excites tech investors but remains a speculative bet.

Kevin Warsh Just Signaled Higher-for-Longer Rates. Here's What That Means for Big Pharma Dividend Stocks.
2026-09-27 09:30 • The Motley Fool Positive Axe Cap view: Selective

Federal Reserve Chair Kevin Warsh's hawkish stance signals sustained higher interest rates to combat inflation. While this increases competition for dividend stocks from Treasury bonds, big pharma dividend stocks like Pfizer, AbbVie, and Bristol Myers Squibb should remain resilient due to strong fundamentals and manageable debt service costs. Historical data shows pharma-specific business factors matter more than interest rates for stock performance.

Axe note: Kevin Warsh’s message on sustained high rates challenges dividend seekers, but pharma firms with solid cash flow remain candidates for income.

Down 23%, Should You Buy the Dip on Sandisk Stock?
2026-09-27 09:25 • The Motley Fool Positive Axe Cap view: Selective

Sandisk stock has pulled back 23% from its June 2026 high despite posting record fiscal Q4 results with 372% revenue growth. The company is benefiting from a major shift toward data center demand for NAND flash memory driven by AI workloads. With $94 billion in long-term customer agreements providing pricing stability and forward earnings multiples below 10x, the stock presents a compelling value opportunity, though cyclical industry risks remain.

Axe note: Sandisk stock slid sharply despite stellar earnings and long-term contracts backing revenue stability.

What we follow

We keep the focus on JSE shares, the rand, and the currency moves that matter most to South African investors.

JSE and rand